Archive for the ‘Insulin & Diabetes’ Category

Higher insulin is a major risk factor for prostate cancer

Thursday, September 2nd, 2010

An important paper was just published in the journal Cancer Epidemiology that provides further evidence of insulin as a tumor promoter in prostate cancer. The authors state:

A higher insulin level has been linked to the risk of prostate cancer promotion…the insulin hypothesis was tested once more prospectively in men with a benign prostatic disorder.”

They proceeded by following 389 patients who had lower urinary tract symptoms without prostate cancer over 8-12 years. There were notable differences between the 44 who developed prostate cancer and the rest who didn’t:

“”Men with prostate cancer diagnosis had a higher systolic and diastolic blood pressure, were more obese as measured by BMI, waist and hip measurements than men who did not have prostate cancer diagnosis at follow-up. These men also had a higher uric acid level, and a higher fasting serum insulin level than men who did not have prostate cancer diagnosis at follow-up.”

All of these accessory factors—blood pressure, BMI, waist and hip circumference, uric acid—are directly related to elevated insulin. Considering the prevalence of both prostate cancer and metabolic syndrome (high insulin), it’s important for clinicians and the public alike to bear in mind the authors’ conclusion:

“Our data support the hypothesis that a higher insulin level is a promoter of prostate cancer. Moreover, our data suggest that the insulin level could be used as a marker of the risk of developing prostate cancer. The present findings also seem to confirm that prostate cancer is a component of the metabolic syndrome. Finally, our data generate the hypothesis that the metabolic syndrome conceals early prostate cancer.

Magnesium reduces inflammation by opposing calcium

Saturday, July 31st, 2010

A paper published last month in the journal Magnesium Research sheds light on the study reported in the last post offering evidence for the link between calcium supplementation and heart attacks. The authors investigated the role of magnesium deficiency in the calcium-activated inflammation of metabolic syndrome.

“The concept that metabolic syndrome is an inflammatory condition may explain the role of Mg [magnesium]. Mg deficiency results in a stress effect and..activates the hypothalamic-pituitary-adrenal axis (HPA) axis and the sympathetic nervous system. The activation of the renin-angiotensin-aldosterone system is a factor in the development of insulin resistance by increasing oxidative stress [and]…leads to an inflammatory phenotype.”

They further describe how this develops an inflammatory milieu in blood vessels:

“One of the earliest events in the acute response to stress is endothelial [blood vessel 'lining'] dysfunction…Experimental Mg deficiency in rats induces a clinical inflammatory syndrome characterized by leukocyte and macrophage activation, synthesis of inflammatory cytokines and acute phase proteins, extensive production of free radicals. An increase in extracellular Mg concentration decreases inflammatory effects, while reduction in extracellular Mg results in cell activation. The effect of Mg deficiency in the development of insulin resistance in the rat model is well documented.”

They then elucidate how magnesium deficiency promotes atherosclerosis with the vascular inflammation characteristic of cardiovascular diseases including heart attacks:

“Inflammation occurring during experimental Mg deficiency is the mechanism that induces hypertriglyceridemia and pro-atherogenic changes in lipoprotein metabolism. The presence of endothelial dysfunction and dyslipidemia triggers platelet aggregability [stickiness], thus increasing the risk of thrombotic events [blood clots]. Oxidative stress contributes to the elevation of blood pressure. The inflammatory syndrome induces activation of several factors, which are dependent on cytosolic [inside the cell] Ca [calcium] activation. Recent findings support the hypothesis that the Mg effect on intracellular Ca 2+ homeostasis may be a common link between stress, inflammation and a possible relationship to metabolic syndrome.

In other words, as calcium goes up in ratio to magnesium cardiovascular inflammation develops. This is important in light of the previous post on calcium supplementation and heart attacks.

The author of a review in the same issue of Magnesium Research notes:

“Hypomagnesemia is associated with an increased incidence of diabetes mellitus, metabolic syndrome, mortality rate from CAD [coronary artery disease] and all causes. Magnesium supplementation improves myocardial metabolism, inhibits calcium accumulation and myocardial cell death; it improves vascular tone, peripheral vascular resistance, afterload and cardiac output, reduces cardiac arrhythmias and improves lipid metabolism. Magnesium also reduces vulnerability to oxygen-derived free radicals, improves human endothelial function and inhibits platelet function, including platelet aggregation and adhesion, which potentially gives magnesium physiologic and natural effects similar to adenosine-diphosphate inhibitors such as clopidogrel [blood clot prevention].”

If you’re reading this, whether you are a man or woman it is highly likely that you have a functional deficiency of magnesium and should not be taking calcium.

Don’t over-medicate high blood pressure

Wednesday, July 21st, 2010

There are still many practitioners treating patients for hypertension who believe that systolic blood pressure should be suppressed to less than 130 mm Hg with medication. Another study just published in JAMA (The Journal of the American Medical Association) adds more evidence that this is not helpful even for individuals with diabetes and coronary artery disease. The authors set out to:

“…determine the association of systolic BP control achieved and adverse cardiovascular outcomes in a cohort of patients with diabetes and CAD (coronary artery disease).”

They analyzed data for 6400 subjects from 862 sites in 14 countries for more than ten years.

“Patients received first-line treatment of either a calcium antagonist or β-blocker followed by angiotensin-converting enzyme inhibitor, a diuretic, or both to achieve systolic BP of less than 130 and diastolic BP of less than 85 mm Hg. Patients were categorized as having tight control if they could maintain their systolic BP at less than 130 mm Hg; usual control if it ranged from 130 mm Hg to less than 140 mm Hg; and uncontrolled if it was 140 mm Hg or higher.”

The data they accumulated painted this picture:

“…little difference existed between those with usual control and those with tight control…The all-cause mortality rate was 11.0% in the tight-control group vs 10.2% in the usual-control group; however, when extended follow-up was included, risk of all-cause mortality was 22.8% in the tight control vs 21.8% in the usual control group.”

Note that the tight control group had a slightly higher risk of all-cause mortality over the longer time period. Besides the greater likelihood of adverse effects with higher doses of medication, lower blood pressure means diminished delivery of oxygen to tissues (the pressure acts to overcome the increased resistance of less a healthy circulatory system).

Their conclusion clearly states the lack of benefit with suppression to less than 130 mm Hg:

Tight control of systolic BP among patients with diabetes and CAD was not associated with improved cardiovascular outcomes compared with usual control.”

See another recent study that proves the same point.

More evidence that metformin can cause vitamin B12 deficiency

Sunday, July 4th, 2010

British Medical JournalPatients with advanced diabetes whose insulin receptors have sustained years of damaging insult sometimes require the medication metformin. Clinicians and patients alike need to bear in mind that metformin tends to cause a deficiency of the critical nutrient cofactor vitamin B12. Research just published in the British Medical Journal reminds us that this is not in question or a matter of opinion. The authors set out to…

“…study the effects of metformin on the incidence of vitamin B-12 deficiency (<150 pmol/l), low concentrations of vitamin B-12 (150-220 pmol/l), and folate and homocysteine concentrations in patients with type 2 diabetes receiving treatment with insulin.”

Incidentally, this reference for vitamin B-12 is extremely low and far from optimal. After following 390 patients with type 2 diabetes who were treated with 850 mg metformin or placebo three times a day for 4.3 years, what did they conclude from their data?

Long term treatment with metformin increases the risk of vitamin B-12 deficiency, which results in raised homocysteine concentrations. Vitamin B-12 deficiency is preventable; therefore, our findings suggest that regular measurement of vitamin B-12 concentrations during long term metformin treatment should be strongly considered.”

Do remember that serum B12 is not a reliable indicator. To ascertain that your genetic and circumstantial needs for this critical cofactor are actually being methylmalonic acid, measured in serum or urine, is much more reliable.

Inflammation and insulin resistance genes are activated by surgery

Monday, June 28th, 2010

Journal of Clinical Endocrinology & MetabolismThis interesting paper recently published in the Journal of Clinical Endocrinology & Metabolism describes one of the reasons why support when undergoing a surgical procedure is so important (and links to the risks for delirium and accelerated dementia after surgery in the elderly). The authors set out to investigate the…

“…mechanisms behind postoperative insulin resistance and impaired glucose utilization…”

They shrewdly analyzed the expression of 21 target genes in abdominal adipose (fat) tissue from samples taken at the beginning and end of patients undergoing abdominal surgery. What did the data show?

“After surgery, both sc [subcutaneous] and omental adipose tissue mRNA levels of genes involved in the IL6 and nicotinamide phosphoribosyltransferase pathways were increased, whereas mRNA levels of insulin receptor substrate 1 and adiponectin were reduced. TNF pathway genes were differently regulated between sc and omental adipose tissue, and glucose transporter 4 mRNA levels were decreased only in omental adipose tissue.”

In other words, surgery elicits a shift in genetic expression that favors insulin resistance and inflammation. The authors conclude:

“The transcriptional output of pivotal inflammatory and insulin signaling pathway genes is altered after surgery…This could be of importance for the metabolic aberrations associated to postsurgical complications…”

This helps to understand why patients who are lucky enough to receive adjunctive support for the insulin and inflammatory signaling pathways and receptors recover faster and with less complications.

Metabolic syndrome (pre-diabetes) is as bad as diabetes for heart attack risk

Thursday, June 24th, 2010

Journal of the American College of CardiologyA study recently published in the Journal of the American College of Cardiology is provides more evidence that the insulin resistance and other aspects of metabolic syndrome leading up to but before diabetes has been established can already do sufficient damage to precipitate a heart attack.

“This study examines the risk of acute myocardial infarction (MI) conferred by the metabolic syndrome (MS) and its individual factors in multiple ethnic populations.”

The authors evaluated data from 26,903 subjects in 52 countries according to the World Health Organization (WHO) and International Diabetes Federation (IDF) criteria for MS, and correlated them with the occurrence of heart attack to calculate the odds. Crunching the numbers produced these results:

“Using the WHO definition, the association with MI by the MS is similar to that of diabetes mellitus and hypertension and significantly stronger than that of the other component risk factors…The IDF definition showed similar results.”

The practical conclusion to be drawn from this evidence is that the evaluation and treatment of metabolic syndrome in general and insulin resistance in particular is mandatory for realistic heart attack risk assessment and prevention.

Support for insulin signaling and inflammation after surgery

Wednesday, June 23rd, 2010

Journal of Clinical Endocrinology & MetabolismSurgeons are routinely surprised at the speed of recovery and reduction of complications and discomfort when they operate on our patients who have a surgical support program based on their individual needs. This interesting study published recently in the Journal of Clinical Endocrinology & Metabolism describes why supporting insulin function and regulation of the inflammatory response help so much.

“The mechanisms behind postoperative insulin resistance and impaired glucose utilization are not fully understood…In this study, we aimed to specifically evaluate the transcription profile of genes in the insulin and adipokine signaling pathways…after surgical injury.”

Adipokines are cytokines such as IL-6 and TNFα secreted by fat cells. The authors measured changes in the messenger RNA (mRNA) levels that code for insulin signaling and inflammatory cytokines to define how genes alter their expression in response to a surgical trauma. Their data showed a signficant effect:

After surgery…adipose tissue mRNA levels of genes involved in the IL6 and nicotinamide phosphoribosyltransferase pathways were increased, whereas mRNA levels of insulin receptor substrate 1 and adiponectin were reduced.”

Their conclusion is important for surgeons and their patients:

The transcriptional output of pivotal inflammatory and insulin signaling pathway genes is altered after surgery…This could be of importance for the metabolic aberrations associated to postsurgical complications, such as insulin resistance and hyperglycemia.”

If you are anticipating an elective procedure and your surgeon is not trained to design a supportive protocol based on an evaluation using the appropriate tests, you may wish to seek out a practitioner experienced in the functional approach.

A new and convenient biomarker for early insulin resistance

Wednesday, June 16th, 2010

PLoS OneElevated levels of insulin due to insulin resistance can do so much damage throughout the body long before the onset of type 2 diabetes that better tools for making the diagnosis early enough for lifestyle changes to have their maximum benefit are always welcome. This research article just published in PLoS One (Public Library of Science) validates the use of an ‘old friend’, α-hydroxybutyrate (α–HB, α = alpha), as a valuable warning sign in the non-diabetic population. The authors first note that…

“Current diagnostic tests, such as glycemic indicators, have limitations in the early detection of insulin resistant individuals. We searched for novel biomarkers identifying these at-risk subjects.”

The authors use of ‘random forest statistical analysis’ of 399 nondiabetic subjects (representing a broad spectrum of insulin sensitivity and glucose tolerance) selected α-hydroxybutyrate (α–HB) as the most accurate biochemical for detecting insulin resistance.

“α–HB also separated subjects with normal glucose tolerance from those with impaired fasting glycemia or impaired glucose tolerance independently of, and in an additive fashion to, insulin resistance. These associations were also independent of sex, age and BMI.”

Thus the authors conclude:

α–hydroxybutyrate is an early marker for both insulin resistance and impaired glucose regulation.

I have been testing α–HB for years as part of an organic acids panel because it is also an indicator of toxin-stimulated upregulation of detoxification pathways and glutathione demand. So it makes sense that the authors would also add:

The underlying biochemical mechanisms may involve increased lipid oxidation and oxidative stress.”

I’m looking at an organic acids report from the file of a patient with other signs of insulin resistance plus a recurrence of breast cancer and, sure enough, α–hydroxybutyrate is abnormally elevated.

Another reminder about insulin and cancer

Tuesday, June 15th, 2010

Postgraduate MedicineA paper published in the most recent issue of Postgraduate Medicine brings to mind the importance of insulin regulation in cancer prevention and treatment. The authors studied the interplay between the use of insulin therapy in diabetes and cancer.

“According to 2007 estimates, 27% of all patients with diabetes use some form of insulin therapy. The increasing utilization of insulin has become a cause for concern because findings from several observational trials have suggested an association with an increased risk of developing cancer.”

The authors undertook a review of scientific studies that assessed the carcinogenic or mitogenic effects of insulin therapy [mitogenic = stimulating mitosis, thus increasing the rate of existing tumor growth]. Here’s how the evidence weighed in:

“Data from our review suggest that insulin analogs…may play more of a mitogenic than a carcinogenic role in association with different types of cancer, suggesting an amplified rate of existing tumor growth in the presence of insulin analogs. Evidence for insulin-induced mitogenicity appears to be most prevalent in prostate, breast, pancreatic, and colorectal cancers.”

I don’t think I can emphasize enough the importance of healthy insulin regulation in cancer prevention and treatment. As the authors state in their conclusion:

“…clinicians must be diligent in both screening for new cancers in patients receiving insulin and in monitoring for tumor growth or maintenance of remission in patients with existing cancers.”

More evidence that coffee helps blood sugar and liver inflammation

Tuesday, May 25th, 2010

Journal of Agricultural and Food ChemistryYet another study on the benefits of coffee was just published in the Journal of Agricultural and Food Chemistry. This ones demonstrates how this salubrious beverage improves insulin function and fatty liver by reducing inflammation. The authors observe:

“Epidemiological surveys have demonstrated that habitual coffee consumption reduces the risk of type 2 diabetes. The aim of this work was to study the antidiabetic effect of coffee and caffeine in spontaneously diabetic KK-Ay mice.”

The mice were not taken to Starbucks for mini espresso shots, but were…

“…given regular drinking water (controls) or 2-fold diluted coffee for 5 weeks.”

The results were pretty amazing:

“Coffee ingestion ameliorated the development of hyperglycemia and improved insulin sensitivity. White adipose tissue mRNA levels of inflammatory cytokines (MCP-1, IL-6, and TNFα), adipose tissue MCP-1 concentration, and serum IL-6 concentration in the coffee group were lower than the control group. Moreover, coffee ingestion improved the fatty liver.”

The authors summed up their findings by stating:

“…coffee exerts a suppressive effect on hyperglycemia by improving insulin sensitivity, partly due to reducing inflammatory cytokine expression and improving fatty liver. Moreover, caffeine may be one of the effective antidiabetic compounds in coffee.”